Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
The JAK/STAT signaling pathway: from bench to clinic
X Hu, J Li, M Fu, X Zhao, W Wang - Signal transduction and targeted …, 2021 - nature.com
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …
COVID-19. Outline the latest treatments available in the management of COVID-19 …
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …
EW Ely, AV Ramanan, CE Kartman… - The Lancet …, 2022 - thelancet.com
Summary Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown
efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) …
efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) …
The transformational role of GPU computing and deep learning in drug discovery
Deep learning has disrupted nearly every field of research, including those of direct
importance to drug discovery, such as medicinal chemistry and pharmacology. This …
importance to drug discovery, such as medicinal chemistry and pharmacology. This …
COVID-19 vaccines: The status and perspectives in delivery points of view
Due to the high prevalence and long incubation periods often without symptoms, the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals …
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals …
Building a knowledge graph to enable precision medicine
Developing personalized diagnostic strategies and targeted treatments requires a deep
understanding of disease biology and the ability to dissect the relationship between …
understanding of disease biology and the ability to dissect the relationship between …
[HTML][HTML] Immunopathogenesis and treatment of cytokine storm in COVID-19
JS Kim, JY Lee, JW Yang, KH Lee, M Effenberger… - Theranostics, 2021 - ncbi.nlm.nih.gov
Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-
inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …
inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …
COVID-19: Discovery, diagnostics and drug development
T Asselah, D Durantel, E Pasmant, G Lau… - Journal of …, 2021 - Elsevier
Summary Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019,
and has since become a pandemic. Groups from China identified and sequenced the virus …
and has since become a pandemic. Groups from China identified and sequenced the virus …